| List I-Mechanism of action | List II-Drugs | ||
| A | DPP4 inhibitors | I | Metformin |
| B | KATP Channel blocker | II | Pioglitazone |
| C | PPAR activator | III | Glimepiride |
| D | AMP Activator | IV | Teneligliptin |
| E | - | V | α glucosidase inhibitors |
Choose the correct answer from the options given below:
| List I | List II | ||
| A | Phase‐I | I | Post marketing surveillance |
| B | Phase‐0 | II | Micro dosing |
| C | Phase‐3 | III | First in human dose |
| D | Phase‐4 | IV | Multicentric trials |
Choose the correct answer from the options given below:
List I | List II | ||
|---|---|---|---|
| A | \(\Omega^{-1}\) | I | Specific conductance |
| B | \(∧\) | II | Electrical conductance |
| C | k | III | Specific resistance |
| D | \(\rho\) | IV | Equivalent conductance |
List I | List II | ||
|---|---|---|---|
| A | Constant heat (q = 0) | I | Isothermal |
| B | Reversible process at constant temperature (dT = 0) | II | Isometric |
| C | Constant volume (dV = 0) | III | Adiabatic |
| D | Constant pressure (dP = 0) | IV | Isobar |